Glenmark Pharmaceuticals achieved a solid performance in the second quarter, with a profit after tax of Rs 354 crore. The company's consolidated total revenue from operations increased to Rs 3,433.8 crore, compared to Rs 3,207.37 crore in the same period last year.

This demonstrates the company's effective cost management and revenue growth. Total expenses for the quarter were slightly lower at Rs 3,000.64 crore, down from Rs 3,008 crore in the corresponding quarter of the previous year.

The company's performance highlights its ability to manage costs efficiently while achieving revenue growth. This is evident from the increase in consolidated total revenue from operations and the slight decrease in total expenses for the quarter.